| Mr Richard S Tockman, MD | |
|
25a June St, Sanford, ME 04073-2642 | |
| (207) 324-8311 | |
| (207) 324-7899 |
| Full Name | Mr Richard S Tockman |
|---|---|
| Gender | Male |
| Speciality | Family Medicine |
| Location | 25a June St, Sanford, Maine |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1689631392 | NPI | - | NPPES |
| B86997 | Other | ME | HARVARD PILGRIM |
| 2071103 | Other | ME | AETNA |
| 321290199 | Medicaid | ME | |
| 025354 | Other | ME | ANTHEM |
| 610109201 | Other | ME | CIGNA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | 009388 (Maine) | Primary |
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1639194509 PECOS PAC ID: 7517860588 Enrollment ID: O20040206000472 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.
Stago has received approval from the US Food and Drug Administration for the reagent STA -Liatest D-Di, in the exclusion of pulmonary embolism (PE) in patients with low or moderate risk, presenting at an emergency unit.
Our cells are more like us than we may think. They're sensitive to their environment, poking and prodding deliberately at their surroundings with hand-like feelers and chemical signals as they decide whether and where to move. Such caution serves us well but has vexed engineers who seek to create synthetic tissue, heart valves, implants and other devices that the human body will accept.
› Verified 4 days ago
| Entity Name | Mainehealth |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790265502 PECOS PAC ID: 7517860588 Enrollment ID: O20040701000166 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.
Stago has received approval from the US Food and Drug Administration for the reagent STA -Liatest D-Di, in the exclusion of pulmonary embolism (PE) in patients with low or moderate risk, presenting at an emergency unit.
Our cells are more like us than we may think. They're sensitive to their environment, poking and prodding deliberately at their surroundings with hand-like feelers and chemical signals as they decide whether and where to move. Such caution serves us well but has vexed engineers who seek to create synthetic tissue, heart valves, implants and other devices that the human body will accept.
› Verified 4 days ago
| Entity Name | Southern Maine Health Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1659392819 PECOS PAC ID: 0143208348 Enrollment ID: O20040713001060 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.
Stago has received approval from the US Food and Drug Administration for the reagent STA -Liatest D-Di, in the exclusion of pulmonary embolism (PE) in patients with low or moderate risk, presenting at an emergency unit.
Our cells are more like us than we may think. They're sensitive to their environment, poking and prodding deliberately at their surroundings with hand-like feelers and chemical signals as they decide whether and where to move. Such caution serves us well but has vexed engineers who seek to create synthetic tissue, heart valves, implants and other devices that the human body will accept.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mr Richard S Tockman, MD Po Box 233, Sanford, ME 04073-0233 Ph: (207) 490-7728 | Mr Richard S Tockman, MD 25a June St, Sanford, ME 04073-2642 Ph: (207) 324-8311 |
News Archive
Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A.
A major research company with expertise in managing clinical trials is partnering with the University of Colorado's Anschutz Medical Campus to more efficiently bring the latest stem cell discoveries from the laboratory to the patient.
Stago has received approval from the US Food and Drug Administration for the reagent STA -Liatest D-Di, in the exclusion of pulmonary embolism (PE) in patients with low or moderate risk, presenting at an emergency unit.
Our cells are more like us than we may think. They're sensitive to their environment, poking and prodding deliberately at their surroundings with hand-like feelers and chemical signals as they decide whether and where to move. Such caution serves us well but has vexed engineers who seek to create synthetic tissue, heart valves, implants and other devices that the human body will accept.
› Verified 4 days ago
Timothy A Theobald, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25a June St Ste 111, Sanford, ME 04073 Phone: 207-490-7998 | |
Mary L Callison, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 10 Goodall Drive, Sanford, ME 04073 Phone: 207-490-7790 | |
Steven J Schneider, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25a June St, Sanford, ME 04073 Phone: 207-324-8311 Fax: 207-324-7899 | |
Melissa Ifantides, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25a June St, Suite 101, Sanford, ME 04073 Phone: 207-490-7998 | |
William F Frank, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 14 Winter St, Sanford, ME 04073 Phone: 207-324-3226 Fax: 207-324-4088 | |
James Edward Chlebowski, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 25a June St, Sanford, ME 04073 Phone: 207-490-7731 Fax: 207-490-7028 |